Journal of Pharmaceutics & Drug Delivery Research ISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Rapid Communication, J Pharm Drug Deliv Res Vol: 1 Issue: 1

Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N,NDimethylaminopropionate (DDAIP)

Susan R. Meier-Davis*, Salma Debar, Richard Martin, Mohamed Hachicha and Bassam Damaj
NexMed Inc. 11975 El Camino Real, Suite 300, SanDiego, CA 9213, USA
Corresponding author : S. Meier-Davis
c/o NexMed Inc., 11975 El Camino Real, Suite 300, San Diego, CA 92130, USA
Tel: 858-222-8041; Fax: 858-587-2131
E-mail: [email protected]
Received: July 03, 2012 Accepted: August 09, 2012 Published: August 13, 2012
Citation: Meier-Davis SR, Debar S, Martin R, Hachicha M, Damaj B (2012) Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N,N- Dimethylaminopropionate (DDAIP). J Pharm Drug Deliv Res 1:1. doi:10.4172/2325-9604.1000102

Abstract

Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N, NDimethylaminopropionate (DDAIP)

Penetration of drug through the stratum corneum to reach the underlying epidermal and dermal layers is a critical step for effective therapy by the topical route. To enhance permeation, various penetration enhancers have been utilized in combination with active drugs. The novel excipient, dodecyl-2-N,Ndimethylaminopropionate (DDAIP), was utilized to assess the epidermal penetration of tolnaftate. Tolnaftate, an anti-fungal agent, is approved as an over-the-counter (OTC) product for the treatment of superficial fungal infections including, athlete’s foot, ringworm and jock itch. Utilizing human cadaver skin mounted on Franz cells, tolnaftate skin flux was evaluated with and without the presence of DDAIP. Over a 24-hour period, DDAIP at a concentration of 0.5% enhanced tolnaftate permeation through human cadaver skin relative to the marketed tolnaftate formulation (1%). Increased tolnaftate penetration may decrease the number of applications and treatment duration required for dermatophyte therapy.

Keywords:

Track Your Manuscript

Share This Page